2026年伊始,中国创新药领域迎来了一笔引人瞩目的交易。1月12日晚,荣昌生物宣布与艾伯维签署独家授权协议,将自主研发的PD-1/VEGF双特异性抗体药物RC148的大中华区以外全球权益授权给后者。荣昌生物将获得6.5亿美元的首付款,并有资格获得高达49.5亿美元的开发、监管及商业化里程碑付款,外加在大中华区以外地区净销售额的两位数分级特许权使用费。从康方生物AK112的50亿美元交易,到三生制药...
Source Link2026年伊始,中国创新药领域迎来了一笔引人瞩目的交易。1月12日晚,荣昌生物宣布与艾伯维签署独家授权协议,将自主研发的PD-1/VEGF双特异性抗体药物RC148的大中华区以外全球权益授权给后者。荣昌生物将获得6.5亿美元的首付款,并有资格获得高达49.5亿美元的开发、监管及商业化里程碑付款,外加在大中华区以外地区净销售额的两位数分级特许权使用费。从康方生物AK112的50亿美元交易,到三生制药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.